In This Section

Program

Please note that this meeting will take place as an in-person event in San Diego and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Friday, September 25

Saturday, September 26

Sunday, September 27

Monday, September 28

Friday, September 25

REGISTRATION

3-9 p.m. | Indigo West Foyer

WELCOME AND OPENING Keynote

6-7:45 p.m. | Indigo ABEF

  • 6 p.m. | Welcome and Introduction of Keynote Speaker
  • 6:15 p.m. | Opening Keynote Lecture
    Targeting RAS in pancreatic cancer
    Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 7:05 p.m. | Rising Star Keynote
    Wired for innervation: Modeling the neural niche in PDAC
    Eileen Carpenter, University of Michigan Medical School, Ann Arbor, Michigan

Opening Reception

7:45-9:30 p.m. | Promenade Plaza

Saturday, September 26

Breakfast

7-8:30 a.m. | Indigo CDCH

Plenary Session 1: From Detection to Interception: Redefining the Earliest Stages of Pancreatic Cancer

8:30-10:15 a.m. | Indigo ABEF

Session Chair: Diane M. Simeone, University of California, San Diego, California

  • 8:30 a.m. | Turning the tide: Transforming the paradigm from advanced treatment to early detection
    Diane M. Simeone
  • 8:55 a.m. | Getting ahead of the tumor: Interception approaches for pancreas cancer
    Ben Z. Stanger, University of Pennsylvania, Philadelphia, Pennsylvania
  • 9:15 a.m. | Who should we target? Defining high-risk populations for pancreatic cancer early detection and interception
    Nuria Malats, Spanish National Cancer Research Centre, Madrid, Spain
  • 9:35 a.m. | Surveillance-detected pancreatic cancers: Updated report from the PRECEDE Consortium*
    Raymond Wadlow, Inova Health System, Fairfax, Virginia
  • 9:42 a.m. | Reinforcing acinar identity through NR5A2 enables pancreatic cancer interception by preventing and reversing precancer*
    Sahar Nissim, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 9:49 a.m. | Discussion / Q&A

Break

10:15-10:30 a.m. | Indigo West Foyer

Stephenson Global Prize Award Presentation and Honorary Lecture

10:30 a.m.-12 p.m. | Indigo ABEF

Lunch on own

12-2 p.m.

Plenary Session 2: Pancreatic Cancer Biology: From Mechanism to Disease Evolution

2-3:45 p.m. | Indigo ABEF

Session Chair: Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts

  • 2:05 p.m. | Organelle-driven metabolic adaptation in pancreatic cancer progression
    Rushika M. Perera, University of California, San Francisco, California
  • 2:25 p.m. | Molecular and clinical divergence of KRAS mutants in pancreatic cancer
    Rohit Chandwani, Weill Cornell Medicine, New York, New York
  • 2:45 p.m. | Plasma WGS in pancreatic cancer
    Faiyaz Notta, University of Toronto, Toronto, Ontario, Canada
  • 3:05 p.m. | Mutant GNAS-mediated epithelial IL-33 upregulation promotes IPMN initiation and progression*
    Yuki Makino, The University of Osaka Department of Gastroenterology and Hepatology, Suita, Japan
  • 3:12 p.m. | Inflammation links KRAS-driven tumor biology to adverse host phenotypes in pancreatic cancer*
    Dina L. Tataran, University of Glasgow, Glasgow. United Kingdom
  • 3:19 p.m. | Discussion / Q&A

Break

3:45-4 p.m. | Indigo West Foyer

Plenary Session 3: Integrating AI and Multi-Omics in Precision Cancer Modeling

4-5:45 p.m. | Indigo ABEF

Session Chair: Colin D. Weekes, Massachusetts General Hospital, Boston, Massachusetts

  • 4:05 p.m. | From multi-omics to autonomous artificial intelligence agents in pancreatic cancer
    Enrique Velázquez Villareal, City of Hope Comprehensive Cancer Center, Duarte, California
  • 4:25 p.m. | Computationally assisted patient finding of pancreatic cancer for improving care delivery and research
    Daniel Alexander King, Monter Cancer Center, Lake Success, New York
  • 4:45 p.m. | The future of oncology is now: AI applications in clinicians’ frontline
    Joo Kyung Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • 5:05 p.m. | The basal cell state maintains pancreatic cancers by controlling an immunosuppressive cell circuit*
    Kate Ryan, Memorial Sloan Kettering Cancer Center, New York, New York
  • 5:12 p.m. | A time-to-event model for pancreatic cancer risk prediction across multiple future intervals using longitudinal structured electronic health records*
    Jifan Gao, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 5:19 p.m. | Discussion / Q&A

Break

5:45-6 p.m. | Indigo West Foyer

Poster Session a/reception

6-8 p.m. | Indigo CDCH

Sunday, September 27

Breakfast

7-8:30 a.m. | Indigo CDCH

“Meet the Expert” Roundtables Session

7:15-8:15 a.m. | Indigo CDCH

Plenary Session 4: The Desmoplastic and Neural Microenvironment of Pancreatic Cancer

8:30-10:15 a.m. | Indigo ABEF

Session Chair: Andreas Trumpp, German Cancer Research Center, Heidelberg, Germany

  • 8:35 a.m. | Profiling and targeting innervating peripheral neurons in pancreatic cancer
    Andreas Trumpp
  • 8:55 a.m. | Extracting mechanisms of cell cross-talk in pancreatic cancer using spatial and single-cell multi-omics
    Nina Steele, University of Cincinnati, Cincinnati, Ohio
  • 9:15 a.m. | Battling a powerful enemy: Understanding pancreatic cancer cachexia
    Min Li, University of Oklahoma Health Campus, Oklahoma City, Oklahoma
  • 9:35 a.m. | Integrated spatial proteomics of human PDAC uncovers an expanded tumor-immune-stroma spectrum with genomic associations*
    Noor Shakfa, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
  • 9:42 a.m. | EMT-associated focal adhesion signaling mediates resistance to RAS inhibition* 
    Joshua H. Choe, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 9:49 a.m. | Discussion / Q&A

break

10:15-10:30 a.m. | Indigo West Foyer

Plenary Session 5: Reimagining Immunotherapy in Pancreatic Cancer

10:30 a.m.-12:15 p.m. | Indigo ABEF

Session Chair: Florencia McAllister, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 10:30 a.m. | Florencia McAllister
  • 10:55 a.m. | Targeting the antigen landscape that emerges after KRAS inhibition for PDAC immunotherapy
    Alex Jaeger, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
  • 11:15 a.m. | Determinants of B cell fate and function in cancer
    Yuliya Pylayeva-Gupta, University of North Carolina, Chapell Hill, North Carolina
  • 11:35 a.m. | A mutant KRAS-targeted peptide vaccine in combination with RAS(ON) multi-selective inhibition and immune checkpoint modulators enhances anti-tumor immunity in preclinical PDAC models*
    Zirui Zhu, Johns Hopkins University, Baltimore, Maryland
  • 11:42 p.m. | CD4+ T cells instruct cancer-associated fibroblasts to promote immune control of pancreatic cancer
    Jessica Hung, University of California, Berkeley, California
  • 11:49 a.m. | Discussion / Q&A

Lunch on Own

12-2 p.m.

Plenary Session 6: The 3 Rs of RAS Inhibition: Response, Resistance, and Rational Combinations

2-3:45 p.m. | Indigo ABEF

Session Chair: Kenneth P. Olive, Herbert Irving Comprehensive Cancer Center, New York, New York

  • 2 p.m. | Cytotoxic chemotherapy potentiates RAS inhibition by constraining adaptive plasticity
    Kenneth P. Olive
  • 2:25 p.m. | Arsen Osipov, Cedars-Sinai Medical Center, Los Angeles, California
  • 2:45 p.m. | Genetic co-gain in MYC and KRAS drives resistance to targeting KRAS signaling in pancreatic ductal adenocarcinoma
    Rosalie Sears, Oregon Health and Science University, Portland, Oregon
  • 3:05 p.m. | Digenic CRISPR screening identifies novel KRAS/FGFR combination therapies for pancreatic cancer*
    Richard Y. Ebright, Broad Institute, Boston, Massachusetts
  • 3:12 p.m. | Encoding adaptive mechanisms of resistance to KRAS inhibition in pancreatic cancer*
    Qingxiang Lin, Massachusetts General Cancer Center, Boston, Massachusetts
  • 3:49 p.m. | Discussion / Q&A

break

3:45-4 p.m. | Indigo West Foyer

Panel Discussion: Accelerating First-in-Human Oncology Trials Through Regulatory Innovation

4-5 p.m. | Indigo ABEF

Moderator: Diane M. Simeone, University of California, San Diego, California

  • Panelists
    Lola Fashoyin-Aje, AstraZeneca, Gaithersburg, Maryland
    Thomas George, University of Florida Health Cancer Center, Gainsville, Florida
    Daniel Alexander King, Monter Cancer Center, Lake Success, New York
  • Topic | Are Current Clinical Trial Models Keeping Pace with Innovation in Pancreatic Cancer?
  • Topic | How Can the U.S. Remain at the Forefront of First-in-Human Oncology Drug Development?
  • Topic | What Regulatory Innovations Can Accelerate First-in-Human and Novel Combination Trials?

Poster Session B/Reception

5-7 p.m. | Indigo CDCH

Monday, September 28

Breakfast

7-8:30 a.m. | Indigo CDCH

Plenary Session 7: Smarter Clinical Trials and Precision Development

8:30-10:15 a.m. | Indigo ABEF

Session Chair: Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York

  • 8:35 a.m. | Changing the paradigm: Novel trial designs in pancreas cancer
    Eileen O’Reilly
  • 8:55 a.m. | A multifaceted analysis of PDAC plasticity in patients
    Colin D. Weekes, Massachusetts General Hospital, Boston, Massachusetts
  • 9:15 a.m. | A new perspective: Clinical trials in the era of RAS-inhibitors
    Christoph Benedikt Westphalen, Ludwig Maximilian University of Munich, Munich, Germany
  • 9:35 a.m. | Navlimetostat (BMS-986504) with or without gemcitabine (GEM) + nab-paclitaxel (nab-P) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC) and homozygous MTAP deletion (MTAP-del) from CA240-0007*
    Tanios Bekaii-Saab, Mayo Clinic, Phoenix, Arizona
  • 9:42 a.m. | Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer*
    Wungki Park, Memorial Sloan Kettering Cancer Center, New York, New York
  • 10:15 a.m. | Discussion / Q&A

break

10:15-10:30 a.m. | Indigo West Foyer

Plenary Session 8: Spatial Biology and Actionable Tumor Ecosystems: Beyond the Pretty Picture

10:30 a.m.-12:15 p.m. | Indigo ABEF

Session Chair: To be announced

  • 10:35 a.m. | Forecasting the interplay between tumor-CAF-immune ecosystems by integrating spatial multiomics and mechanistic mathematical modeling
    Elana Fertig, University of Maryland, Baltimore, Maryland
  • 10:55 a.m. | Spatial microenvironment alterations across the clinical spectrum and genomic landscape of human PDAC
    Hartland Jackson, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada                      
  • 11:15 a.m. | Decoding actionable tumor ecosystems through spatial multi-omics and AI
    Linghua Wang, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 11:35 a.m. | High-plex spatial phenotyping resolves immune organization in pancreatic ductal adenocarcinoma*
    Deniz G. Olgun, Massachusetts General Hospital, Boston, Massachusetts
  • 11:42 a.m. | Clonal heterogeneity in human pancreatic ductal adenocarcinoma and its impact on tumor progression*
    Sungsik Kim, UC San Diego, La Jolla, California
  • 11:49 a.m. | Discussion / Q&A

Closing Remarks

12:15 p.m. | Indigo ABEF